Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026)

C4 Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $9.8 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 22.19% year-over-year to $9.8 million; the TTM value through Mar 2026 reached $9.8 million, down 22.19%, while the annual FY2025 figure was $13.3 million, 31.24% down from the prior year.
  • Accumulated Expenses for Q1 2026 was $9.8 million at C4 Therapeutics, down from $13.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $20.6 million in Q4 2023 and troughed at $6.7 million in Q1 2022.
  • A 5-year average of $14.7 million and a median of $15.4 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 529.94% in 2022 and later tumbled 33.03% in 2024.
  • Year by year, Accumulated Expenses stood at $19.8 million in 2022, then grew by 4.36% to $20.6 million in 2023, then dropped by 6.14% to $19.4 million in 2024, then tumbled by 31.24% to $13.3 million in 2025, then fell by 26.17% to $9.8 million in 2026.
  • Business Quant data shows Accumulated Expenses for CCCC at $9.8 million in Q1 2026, $13.3 million in Q4 2025, and $11.3 million in Q3 2025.